3,0
7 ene 2015
Empleado anónimo
Exempleado
Recomendar
Aprobación del CEO
Perspectiva de la empresa
Ventajas
Diversity in Oncology portfolio, very strong in oncology.
Desventajas
Its strength in oncology is due to its subsidiary: Genentech. It has no historical experience in oncology. While Genentech is open, dynamic, and innovative; Roche is stiff and very conservative...it could not make drug development by itself.